CytoDel's Unattributed Round

CytoDel raised a round of funding on January 17, 2018.

CytoDel is a biopharmaceutical company that uses the tools of 21st century molecular biology to produce recombinant derivatives of botulinum neurotoxin (BoNT). The technology allows the Company to man…

Articles about CytoDel's Unattributed Round: